Therapeutic window assays for NK-engagers: Killing activity tumor cells vs progenitors

Ex vivo estimation of Daratumumab Hematotoxicity in Killing Progenitors results in a Therapeutic Window assay

  • Daratumumab is less active on Healthy CD34+CD38- progenitor cells.
Figure 1 Dose Response Curves Of Daratumumab

Figure 1. Dose response curves of daratumumab in plasmatic and progenitor cells

  • Specificity & Therapeutic Window ex vivo is higher at High CD38 Expression
Figure 2 Correlation Between CD38

Figure 2. Correlation between CD38 expression on different cellular subsets and activity (AUC) in MM patients

  • Hematotoxicity:
  • Daratumumab Less Active on Progenitor Cells
  • Specificity & Therapeutic Window depend on CD38 expression on tumoral cells
Click Here